Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

9 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Pulmonary sub-cohort

- 01/07/2021 - 1 Formulário, 6 Grupos de itens, 30 Elementos de dados, 1 Idioma
Grupos de itens: Chronic pulmonary disease other than asthma and copd, Oxygen ventilation/ oxygen support before SARS-CoV-2 detection, Regular use of inhaler, Prior pulmonary function (Spirometrie) before COVID-19, Pulmonary function (Spirometrie) at diagnosis of COVID-19, Is data entry for this section finished?
Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 21.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. This document is for the pulmonary sub-cohort. If a text field can't be filled out, note 'ND'.

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Pulmonary sub-cohort

- 16/07/2021 - 23 Formulários, 6 Grupos de itens, 30 Elementos de dados, 1 Idioma
Grupos de itens: Chronic pulmonary disease other than asthma and copd, Oxygen ventilation/ oxygen support before SARS-CoV-2 detection, Regular use of inhaler, Prior pulmonary function (Spirometrie) before COVID-19, Pulmonary function (Spirometrie) at diagnosis of COVID-19, Is data entry for this section finished?
Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. Please note that only cases with known outcome are collected! Baseline / diagnosis is defined as the day the sample of the first positive SARS-CoV-2 result was taken. Criteria of the Uncomplicated Phase: Asymptomatic OR Symptoms of upper respiratory tract infection and/or Nausea, emesis, diarrhea and/or Fever Remember: The Uncomplicated Phase ends, if a previously febrile patient has no fever anymore and has completed 14 days of follow-up without entering Complicated or Critical Phase; then move to Recovery Phase. Also, as soon as one of the criteria of the Complicated or Critical Phase are fulfilled, Uncomplicated Phase ends; move over to there. If the patient has died, the phase ends with the death of the patient. If the patient has died, do not report terminal values, e.g. those recorded after switching off life-support or heart rate "0" after death of the patient. Criteria of the Complicated Phase: * Need for oxygen supplementation (In patients with prior oxygen home therapy, clinically meaningful increase in need for oxygenation.) * paO2 at room air < 70 mmHg * SO2 at room air < 90 % * GOT or GPT > 5x ULN * New cardiac arrhythmia * New pericardial effusion >1cm * New heart failure with pulmonary edema, congestive hepatopathy or peripheral edema Remember: The Complicated Phase ends, if none of the criteria for the Complicated Phase is fulfilled anymore AND the patient is free of fever; then move to Recovery Phase. Also, as soon as one of the criteria of the Critical Phase are fulfilled, Complicated Phase ends; move over to Critical Phase. If the patient has died, the phase ends with the death of the patient. If the patient has died, do not report terminal values, e.g. those recorded after switching off life-support or heart rate "0" after death of the patient. Criteria of the Critical Phase: * Need for catecholamines * Life-threatening cardiac arrhythmia * Mechanical ventilation (invasive or non-invasive) * Liver failure with Quick< 50% * qSOFA >= 2 * Renal failure in need of dialysis Remember: The Critical Phase ends as soon as none of the criteria for the Critical Phase is fulfilled anymore AND the patient is free of fever. If the patient has died, it ends with the death of the patient. If the patient has died, do not report terminal values, i.e. those recorded after turning off life-support or heart rate "0" after death of the patient. Criteria of the Recovery Phase: *Improvement by at least one phase, i.e. Critical to Complicated or Complicated to Uncomplicated * Defervescence Remember: Uncomplicated asymptomatic patients enter recovery phase after 14 days of observation without disease progression No further progression or re-hospitalization If a text field can't be filled out, note 'ND' (for not determined).

Baseline I

39 Grupos de itens 280 Elementos de dados

Emergency care details

11 Grupos de itens 43 Elementos de dados

Recovery Phase

15 Grupos de itens 80 Elementos de dados

Uncomplicated Phase

20 Grupos de itens 120 Elementos de dados

Complicated Phase

28 Grupos de itens 155 Elementos de dados

Critical Phase

32 Grupos de itens 188 Elementos de dados

Study SHIP-TREND_TREND1_PIA - t1.allergyresp

- 26/10/2024 - 26 Formulários, 1 Grupo de itens, 24 Elementos de dados, 2 Idiomas
Grupo de itens: t1.allergyresp
SHIP Study https://doi.org/10.1093/ije/dyac034

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Baseline I

- 24/06/2021 - 1 Formulário, 39 Grupos de itens, 280 Elementos de dados, 1 Idioma
Grupos de itens: Sociodemography, Comorbidities, Central nervous system / Neurological disesases, Comorbidities, Cardiovascular diseases, Comorbidities, Pulmonary diseases, Comorbidities, Hematological / oncological diseases, Comorbidities, Rheumatological diseases, Comorbidities, Allergology, Comorbidities, Other internal disorders, Comorbidities, Other conditions, Body-Mass-Index (BMI), Smoking status, Use of e-cigarettes and / or vaporizer?, Pre-existing treatment, Recent immunosuppressive medication, Colonisation with multi-resistant pathogens, Disease limiting life expectancy before positive SARS-CoV-2 testing, Follow-up duration after SARS-CoV-2 diagnosis, Last known status, Diagnosis context, COVID-19 diagnosis details, Complications at baseline: Thrombotic and thromboembolic manifestations, Complications at baseline: Neurological, Complications at baseline: Other severe organ damage, Complications at baseline: Other, Disease course, Duration (days) of..., Symptoms: Please click all symptoms which occurred in the respective clinical phase, Vitals, Lung ultrasound results at SARS-CoV-2 detection, Baseline: Chest CT results at SARS-CoV-2 detection, Heart function, Echocardiography: Ejection fraction (EF) at SARS-CoV-2 detection, Cardiovascular magnetic resonance imaging (CMR) performed in any clinical phase, Neurological diagnostic in various phases, Complementary and/or integrative medicine (CIM) used in any phase, Discussion of limitation of therapy during SARS-CoV-2 infection, Specialist palliative care during SARS-CoV-2 infection, Agreement to share data for scientific purposes, Biomaterial availability for research proposes, Participation in interventional clinical trials
Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. This document is for baseline information. A related document "Baseline II" documents further baseline information related to baseline timepoint and to disease periods. Baseline / diagnosis is defined as the day the sample of the first positive SARS-CoV-2 result was taken. Please note that only cases with known outcome are collected! If a text field can't be filled out, note 'ND' (for not determined).

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Emergency care details

- 29/06/2021 - 1 Formulário, 11 Grupos de itens, 43 Elementos de dados, 1 Idioma
Grupos de itens: Lung ultrasound in emergency department for COVID-19 diagnosis, result, Initial therapeutic approaches for COVID-19 treatment in emergency department, respiratory / airway management in the emergency department, Oxygen inhalation, High flow nasal cannula, Mechanical ventilation settings, BIPAP settings, Mechanical ventilation: mean positive endexpiratory pressure (PEEP), Mechanical ventilation: mean fraction of inspired oxygen (FIO2), Information concerning admission at / discharge from emergency department, Is data entry for this section finished?
Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 21.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. This document is for Emergency care details. If a text field can't be filled out, note 'ND'.

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Recovery Phase

- 28/06/2021 - 1 Formulário, 15 Grupos de itens, 80 Elementos de dados, 1 Idioma
Grupos de itens: RC: Respiratory findings, RC: Cardiovascular findings, RC: Neurological findings, RC: Further findings, RC: Vitals, RC: Lung ultrasound, RC: worst chest CT result, RC: Co/Superinfections, RC: Antibacterial treatment: Betalactams, RC: Antibacterial treatment: Macrolides, RC: Antibacterial treatment: Other antibacterial treatment, RC: Multiple sclerosis, severity after COVID-19 infection, RC: Pulmonary function test (Spirometry), RC: Deterioration of prior chronic pulmonary disease, RC: Is data entry for this section finished?
Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. This document is for data aggregated in the recovery phase. If a text field can't be filled out, note 'ND'. Criteria of the Recovery Phase: Improvement by at least one phase, i.e. Critical to Complicated or Complicated to Uncomplicated Defervescence Remember: Uncomplicated asymptomatic patients enter recovery phase after 14 days of observation without disease progression No further progression or re-hospitalization

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Uncomplicated Phase

- 15/06/2021 - 1 Formulário, 20 Grupos de itens, 120 Elementos de dados, 1 Idioma
Grupos de itens: UC: Feeling of breathlessness, UC: Fever, UC: Vital signs, UC: Lung ultrasound, UC: worst chest CT result, UC: Antivirals, UC: Antibiotics, UC: Antifungals, UC: Immunomodulators, UC: Cardiovascular medication, UC: Non-oral anticoagulants, UC: Oral anticoagulants, UC: Platelet aggregation inhibition, UC: Further anticoagulation / platelet aggregation inhibition, UC: Other COVID-19 related therapy, UC: Co/Superinfections, UC: Antibacterial treatment: Betalactams, UC: Antibacterial treatment: Macrolides, UC: Antibacterial treatment: Other antibacterial treatment, UC: Is data entry for this section finished?
Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. This document is for data aggregated in the uncomplicated phase. If a text field can't be filled out, note 'ND'. Criteria of the Uncomplicated Phase: Asymptomatic OR Symptoms of upper respiratory tract infection and/or Nausea, emesis, diarrhea and/or Fever Remember: The Uncomplicated Phase ends, if a previously febrile patient has no fever anymore and has completed 14 days of follow-up without entering Complicated or Critical Phase; then move to Recovery Phase. Also, as soon as one of the criteria of the Complicated or Critical Phase are fulfilled, Uncomplicated Phase ends; move over to there. If the patient has died, the phase ends with the death of the patient. If the patient has died, do not report terminal values, e.g. those recorded after switching off life-support or heart rate "0" after death of the patient.

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Complicated Phase

- 22/06/2021 - 1 Formulário, 28 Grupos de itens, 155 Elementos de dados, 1 Idioma
Grupos de itens: CO: Symptoms / Findings, CO: Feeling of breathlessness, CO: Fever, CO: Vitals, CO: Lung ultrasound, CO: worst chest CT result, CO: Antivirals, CO: Antibiotics, CO: Antifungals, CO: Immunomodulators, CO: Cardiovascular medication, CO: Non-oral anticoagulants, CO: Oral anticoagulants, CO: Platelet aggregation inhibition, CO: Further anticoagulation / platelet aggregation inhibition, CO: Other COVID-19 related therapy, CO: Co/Superinfections, CO: Antibacterial treatment, Betalactams, CO: Antibacterial treatment: Macrolides, CO: Antibacterial treatment: Other antibacterial treatment, CO: Complications, Thrombotic and thromboembolic manifestations, CO: Complications, Neurological, CO, Ischemic stroke: TOAST classification, CO, Ischemic stroke: NIHSS score in acute phase, CO: Complications, Other, CO, Acute kidney injury (KDIGO criteria), CO: SOFA score, CO: Is data entry for this section finished?
Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. This document is for data aggregated in the complicated phase. If a text field can't be filled out, note 'ND'. Criteria of the Complicated Phase: Need for oxygen supplementation (In patients with prior oxygen home therapy, clinically meaningful increase in need for oxygenation.) paO2 at room air < 70 mmHg SO2 at room air < 90 % GOT or GPT > 5x ULN New cardiac arrhythmia New pericardial effusion >1cm New heart failure with pulmonary edema, congestive hepatopathy or peripheral edema Remember: The Complicated Phase ends, if none of the criteria for the Complicated Phase is fulfilled anymore AND the patient is free of fever; then move to Recovery Phase. Also, as soon as one of the criteria of the Critical Phase are fulfilled, Complicated Phase ends; move over to Critical Phase. If the patient has died, the phase ends with the death of the patient. If the patient has died, do not report terminal values, e.g. those recorded after switching off life-support or heart rate "0" after death of the patient.

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Critical Phase

- 23/06/2021 - 1 Formulário, 32 Grupos de itens, 188 Elementos de dados, 1 Idioma
Grupos de itens: CR: Cardiovascular findings, CR: Respiratory findings, CR: Other severe organ damage, CR: Fever, CR: Vitals, CR: Lung ultrasound, CR: worst chest CT result, CR: Antivirals, CR: Antibiotics, CR: Antifungals, CR: Immunomodulators, CR: Cardiovascular medication, CR: Non-oral anticoagulants, CR: Oral anticoagulants, CR: Platelet aggregation inhibition, CR: Further anticoagulation / platelet aggregation inhibition, CR: Other COVID-19 related therapy, CR: ICU treatment, CR: Mechanical ventilation, CR: Other extracorporeal support, CR: Co/Superinfections, CR: Antibacterial treatment: Betalactams, CR: Antibacterial treatment: Macrolides, CR: Other antibacterial treatment, CR: Complications, Thrombotic and thromboembolic manifestations, CR: Complications, Neurological, Ischemic stroke: TOAST classification, Ischemic stroke: NIHSS score in acute phase, CR: Complications, Other, Acute kidney injury (KDIGO criteria), CR: SOFA score, CR: Is data entry for this section finished?
Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. This document is for data aggregated in the critical phase. If a text field can't be filled out, note 'ND'. Criteria of the Critical Phase: Need for catecholamines Life-threatening cardiac arrhythmia Mechanical ventilation (invasive or non-invasive) Liver failure with Quick< 50% qSOFA >= 2 Renal failure in need of dialysis Remember: The Critical Phase ends as soon as none of the criteria for the Critical Phase is fulfilled anymore AND the patient is free of fever. If the patient has died, it ends with the death of the patient. If the patient has died, do not report terminal, i.e. those recorded after turning off life-support or heart rate "0" after death of the patient.

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial